571 Background: Limited data describe the cardiovascular safety of bevacizumab (B) exposure after anthracycline-based adjuvant chemotherapy. We sought to examine rates of cardiovascular dysfunction during and following treatment with adjuvant B for breast cancer. Methods: DFCI 05-055 was a phase II pilot study for patients (pts) with residual invasive carcinoma following neoadjuvant chemotherapy for stage II-III breast cancer. Four sequential 40 pt cohorts were treated with B 15 mg/kg every 3 weeks for 12 months (mo) as monotherapy, with metronomic chemotherapy for 6 mo, with capecitabine 14 day (d) on/7d off for 18 weeks, or 7d on/7d off for 6 mo. Concurrent endocrine and/or trastuzumab therapy was allowed. The primary endpoint was feasibility and tolerability of the combination therapy. Pts underwent cardiac evaluation by MUGA at baseline and 6 mo; a small subset also had MUGA 1 year after completing B. Blood pressure was monitored at each visit and toxicity was graded per CTCAE v.3. Results: 163 pts (m...